ClinicalTrials.Veeva

Menu

PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Candela Corporation logo

Candela Corporation

Status

Completed

Conditions

Benign Pigmented Lesions
Facial Wrinkles

Treatments

Device: PicoWay™ 730nm wavelength
Device: PicoWay™ 1064nm fractional handpiece
Device: PicoWay™ 532nm fractional handpiece

Study type

Interventional

Funder types

Industry

Identifiers

NCT03774849
PWY18010

Details and patient eligibility

About

Evaluation of the PicoWay™ Laser System With 730nm and Resolve™ Fusion Handpieces for Treatment of Benign Pigmented Lesions and Wrinkles.

Full description

Subjects will receive up to 4 study treatments with the PicoWay™ 730 nm laser wavelength, PicoWay™1064nm fractional handpiece and/or PicoWay™ 1064nm fractional handpiece for treatment of benign pigmented lesions or wrinkles. Subjects will return for three follow-up visit evaluations 1-month, 2-months and 3-months post final study treatment. Primary efficacy assessed by masked photographic evaluation. Optional biopsy collection for histological analysis of laser tissue effects.

Enrollment

115 patients

Sex

All

Ages

21 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  1. Willing to provide signed informed consent
  2. Adults age 21 to 80
  3. Fitzpatrick Skin Type (FST) I to VI
  4. Presence of benign pigmented Lesions assessed at baseline as Pigment Severity Score (PSS) of "2" or higher and/or wrinkles assessed at baseline as Fitzpatrick Wrinkle Score (FWS) of "2" or higher
  5. Willing to allow photographs and/or video to be taken of treated areas for the purposes of this research study
  6. Willing to abstain from any other procedures for treatment of benign pigmented lesions or wrinkles in the laser treatment areas for the duration of the study including surgery, light, laser, ultrasound or radiofrequency treatments
  7. Willing to abstain from use of prescription cosmetic products for treatment of benign pigmented lesions or wrinkles in the laser treatment areas for the duration of the study including injections of neurotoxins or dermal fillers, skin lightening creams, and wrinkle creams
  8. Willingness to adhere to study treatment and follow-up visit schedules

Exclusion Criteria

  1. Pregnant, planning pregnancy or breast feeding
  2. Allergy to topical or injectable lidocaine or similar medications
  3. Allergy to topical steroid or similar medications
  4. Unprotected sun exposure in the six weeks prior to enrollment, or active tan in the laser treatment area
  5. History of melanoma in the intended treatment area
  6. History of keloid or hypertrophic scar formation
  7. Use of topical or systemic retinoid therapy during the past six (6) months
  8. Use of neurotoxins in the intended treatment area within the past three (3) months or throughout the duration of the study
  9. Use of dermal fillers in the intended treatment area within the last six (6) months or throughout the duration of the study
  10. Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment.
  11. Open wound or infection in the intended treatment area
  12. History of light induced seizure disorders
  13. Dermatologic and/or cosmetic procedures in the intended treatment area(s) during the past six months
  14. The subject is not suitable, in the opinion of the clinician, for participation in the study due to medical or other reasons that could compromise the study integrity or subject safety

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

115 participants in 3 patient groups

Picoway™ 532nm fractional handpiece
Experimental group
Description:
Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
Treatment:
Device: PicoWay™ 730nm wavelength
PicoWay™ 730nm wavelength
Experimental group
Description:
PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
Treatment:
Device: PicoWay™ 532nm fractional handpiece
PicoWay ™1064nm fractional handpiece
Experimental group
Description:
Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
Treatment:
Device: PicoWay™ 1064nm fractional handpiece

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems